Provigil Generic Exclusivity Decision “Eviscerates” Hatch-Waxman, FTC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In a strongly worded amicus brief filed in Mylan’s lawsuit against FDA, the Federal Trade Commission says it would have required different remedies in clearing Teva’s acquisition of Cephalon last year had it known the Israel-based firm would receive sole 180-day marketing exclusivity for modafinil.